4955
Jun 24, 2022 10:09:39 PM EDT
Q !!Hs1Jq13jV6
Jun 24, 2022 9:52:15 PM EDT
Anonymous
Throw us a bone Q, we’ve all been waiting for what seemed like an eternity.What’s going on?
>>16505361
It had to be done this way.
Q
4966
Nov 27, 2022 8:06:20 PM EST
Q !!Hs1Jq13jV6
What is coded in your DNA?
Who put it there?
Why?
Mankind is repressed.
We will be repressed no more.Information is knowledge.
Knowledge is power.Information is power.
How do you protect your DNA?
There is a war for your DNA.
Protect your DNA.
Ascension.
Q
HB Ad Slot
HB Mobile Ad Slot
Return of the BIOSECURE Act: What Life Sciences Companies Need to Know
by: James W. Kim, Cate Baskin, Eyasu Yirdaw, Polsinelli PC - Alerts
Thursday, December 11, 2025
Key Takeaways
House advances BIOSECURE Act as part of NDAA legislation. The latest version would bar contractors and federal funding recipients from using certain biotechnology equipment or services linked to foreign adversaries, with a Senate vote expected next week.
Proposed restrictions reflect growing national security concerns around biotech. If enacted, the law would restrict federal dollars from flowing to companies linked to national security risks, prompting new compliance obligations across the life sciences sector.
Life sciences companies should begin evaluating supply chain exposure. Although implementation may take years, early planning will be essential as vendor eligibility, contract terms and subrecipient policies come under new scrutiny.
A key provision targeting foreign biotechnology firms is back on the table. On Oct. 9, 2025, the U.S. Senate adopted an amendment to add a version of the BIOSECURE Act — Section 881, Prohibition on Contracting with Certain Biotechnology Providers — to its version of the FY 2026 National Defense Authorization Act (NDAA), a bill widely considered “must-pass” legislation. Yesterday, the House passed its own modified version of the 2026 NDAA, including the BIOSECURE Act under Section 851. The Senate is expected to vote on the bill sometime next week.
If enacted, the BIOSECURE Act would prospectively bar the use of certain “biotechnology equipment or services” from “biotechnology companies of concern” in the performance of federal procurement contracts, grants and loans. The House is expected to vote on the compromise NDAA this week. Once the FY 2026 NDAA is enacted, we will update this alert with a brief summary of the final BIOSECURE Act requirements included in the legislation. Life sciences companies that work with or receive funding from federal agencies should take note, as the measure could trigger long-term changes in vendor eligibility, contract structures and compliance planning. For additional background, see our May client alert, “Trump EO Promotes Domestic Biopharma.”
https://natlawreview.com/article/return-biosecure-act-what-life-sciences-companies-need-know
DNA PROTECTED
NOW WHAT?